US2021213028A1PendingUtilityA1

Novel formulation of meloxicam

77
Assignee: ICEUTICA PTY LTDPriority: Jun 9, 2014Filed: Mar 18, 2021Published: Jul 15, 2021
Est. expiryJun 9, 2034(~7.9 yrs left)· nominal 20-yr term from priority
A61K 31/5415A61K 31/00Y10T428/2982A61K 9/145A61P 25/04A61K 9/1623A61K 9/14A61K 9/1652A61P 29/00A61K 9/4858A61K 9/0053A61K 9/1617A61P 19/02
77
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam.

Claims

exact text as granted — not AI-modified
1 . A unit dosage form of a pharmaceutical composition comprising 5 mg of meloxicam, wherein a single dose, upon oral administration to a population of healthy adults in the fasted state, provides a mean plasma AUC (0-∞) of 7500-20000 h*ng/ml. 
     
     
         2 .- 12 . (canceled) 
     
     
         13 . A unit dosage form comprising 10 mg of meloxicam, wherein a single dose, upon oral administration to a population of healthy adults in the fasted state, provides a mean plasma AUC (0-∞) of 16000-44000 h*ng/ml. 
     
     
         14 .- 30 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.